Curated News
By: NewsRamp Editorial Staff
December 17, 2025
Kairos Pharma Wins 2025 Award for Prostate Cancer Drug Breakthrough
TLDR
- Kairos Pharma's award-winning ENV-105 offers investors a competitive edge by targeting treatment resistance in advanced prostate cancer with promising Phase 2 trial results.
- Kairos Pharma's ENV-105 is a CD105-targeting monoclonal antibody that works by reversing drug resistance to restore effectiveness of standard cancer therapies in clinical trials.
- Kairos Pharma's ENV-105 development addresses significant unmet medical needs in prostate cancer, potentially improving treatment outcomes and quality of life for patients worldwide.
- Kairos Pharma won a 2025 Clinical Trials Arena award for ENV-105, a first-in-class antibody targeting CD105 to overcome cancer treatment resistance in ongoing trials.
Impact - Why it Matters
This development matters because metastatic castration-resistant prostate cancer (mCRPC) is a lethal and treatment-resistant form of cancer with limited effective options, leading to poor patient outcomes. A therapy like ENV-105, which targets the specific biological mechanism of drug resistance (CD105), represents a paradigm shift in oncology. If successful, it could not only extend survival and improve quality of life for prostate cancer patients but also validate a new approach to overcoming treatment resistance that could be applied to other cancers like lung cancer, where Kairos is also testing the drug. For the biopharmaceutical industry and investors, it signals progress in a high-need therapeutic area and highlights the value of innovative R&D targeting fundamental cancer biology. For patients and families, it offers tangible hope for a more effective treatment strategy in the near future.
Summary
Kairos Pharma Ltd. (NYSE American: KAPA), a Los Angeles-based clinical-stage biopharmaceutical company, has achieved significant recognition by winning the prestigious 2025 Clinical Trials Arena Excellence Awards in the Research and Development category for Advanced Prostate Cancer. This award specifically honors the company's groundbreaking work on its lead candidate, ENV-105 (carotuximab), a first-in-class monoclonal antibody designed to target the CD105 protein. The core achievement stems from positive interim safety and efficacy results from a Phase 2 randomized clinical trial, where ENV-105 was evaluated in combination with apalutamide for treating metastatic castration-resistant prostate cancer (mCRPC). This form of prostate cancer is notoriously difficult to treat as it becomes resistant to standard hormone therapies, representing a critical unmet medical need in oncology.
The company's innovative approach focuses on utilizing structural biology to overcome drug resistance, a major hurdle in cancer treatment. ENV-105 is engineered to target CD105, a protein identified as a key driver of resistance to various cancer therapies. By blocking CD105, which becomes elevated in response to standard treatments, ENV-105 aims to reverse this resistance and restore the effectiveness of existing therapies, potentially offering a new lifeline for patients. Beyond the advanced prostate cancer trial, Kairos Pharma is also investigating ENV-105 in a Phase 1 trial for lung cancer, underscoring its broad potential application across multiple cancer types where resistance is a problem. For more details, the full press release is available via the InvestorBrandNetwork.
This news was disseminated through the specialized communications platform InvestorWire, which is part of the broader Dynamic Brand Portfolio managed by IBN. InvestorWire provides advanced wire-grade press release syndication, article syndication to over 5,000 outlets, enhanced press release services, and extensive social media distribution, ensuring that news from companies like Kairos Pharma reaches a wide audience of investors, journalists, and the general public. The announcement also directs interested parties to the company's newsroom for the latest updates and includes standard disclaimers regarding the content provided. This distribution mechanism highlights how modern financial and medical news is amplified through dedicated networks to achieve maximum impact and recognition in crowded information markets.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma Wins 2025 Award for Prostate Cancer Drug Breakthrough
